Multi-Domain CAR T-Cell Composition for Antigen-Independent Expansion

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing chimeric antigen receptors (CARs) for T cells do not adequately support extensive T-cell proliferation, which is crucial for effective tumor immunotherapy.

Innovation Solution

Designing CARs with specific domains, including an antigen binding domain, hinge domain, transmembrane domain, costimulatory signaling region, and CD3 zeta signaling domain, to enhance T-cell activation, expansion, and persistence, allowing antigen-independent proliferation without exogenous cytokines or feeder cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional CAR structures are used, then T cells can be activated, but extensive T-cell proliferation is not adequately supported

Engineering Contradiction:
ImproveT-cell proliferationVSAvoidCAR functionality
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent combines multiple signaling domains (CD3 zeta, CD28, and OX40) into a single CAR construct to achieve synergistic effects. This merging of signaling pathways enables both robust T-cell activation and extensive proliferation, resolving the contradiction between maintaining CAR functionality and achieving high productivity through proliferation.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The CAR construct is designed as a composite signaling molecule integrating extracellular antigen-binding domain, transmembrane domain, and multiple intracellular signaling domains. This composite structure combines the activating signals from different co-stimulatory molecules to enhance both activation and proliferation capabilities simultaneously.

Inventive Principle:
Principle #40Composite materials

2Productivity

If CARs are designed to enhance proliferation, then T-cell expansion increases, but persistence and activation may be compromised

Engineering Contradiction:
ImproveT-cell expansionVSAvoidT-cell persistence
Core Design Contradiction:
ProductivityVSDuration of action of stationary object

Solution Approach 1:

The CAR design provides continuous signaling capability through multiple co-stimulatory domains that sustain T-cell activation and proliferation over time. The combined CD28 and OX40 signaling domains ensure continuous useful action by maintaining both acute activation signals and sustained proliferative signals, preventing exhaustion and enhancing long-term persistence.

Inventive Principle:
Principle #20Continuity of useful action

Solution Approach 2:

The CAR construct dynamically responds to antigen stimulation by activating multiple signaling pathways that adapt to different stimulation intensities. The presence of multiple signaling domains allows the system to dynamically balance activation, proliferation, and persistence responses based on the magnitude and duration of antigen exposure.

Inventive Principle:
Principle #15Dynamics

3Reliability

If multiple signaling domains are incorporated into CAR, then T-cell function improves, but CAR complexity increases

Engineering Contradiction:
ImproveT-cell functionVSAvoidCAR structure
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The CAR construct is designed as a universal multi-functional molecule that integrates antigen recognition, signal transduction, co-stimulation, and proliferation enhancement in a single chimeric protein. This multi-functionality reduces the need for separate molecular components while achieving reliable T-cell function through the coordinated action of integrated domains.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Data Source

PatentUS12350334B2Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
Publication Date: 2025.07.08 THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
  • US12350334B2 patent drawing
  • US12350334B2 patent drawing
  • US12350334B2 patent drawing

AI summary

The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.